Survey of Ophthalmology
Volume 47 , Pages S6-S12 , August 2002

Ocular and Systemic Pharmacokinetics Of Latanoprost in Humans

  • Birgitta Sjöquist, PhD
    • ,
  • Johan Stjernschantz, MD, PhD

      Affiliations

    • Corresponding Author InformationReprint address: Johan Stjernschantz, MD, PhD, Department of Neuroscience, Unit of Pharmacology, Uppsala University, Box 593, BMC, SE-751 24 Uppsala, Sweden

References 

  1. Basu S, Sjöquist B, Resul B, Stjernschantz J. Presence of a 15-ketoprostaglandin Δ13-reductase in porcine cornea. Acta Chem Scand. 1992;46:108–110
  2. Basu S, Sjöquist B, Stjernschantz J, Resul B. Corneal permeability to and ocular metabolism of phenyl substituted prostaglandin esters in vitro. Prostaglandins Leukotrienes Essential Fatty Acids. 1994;50:161–168
  3. Basu S, Sjöquist B. Development of a radioimmunoassay for latanoprost and its application in a long-term study in monkeys. Prostaglandins Leukotrienes Essential Fatty Acids. 1996;55:427–432
  4. Bito LZ. Accumulation and apparent active transport of prostaglandins by some rabbit tissues in vitro. J Physiol (London). 1972;221:371–387
  5. Bito LZ, Salvador EV. Intraocular fluid dynamics. III. The site and mechanism of prostaglandin transfer across the blood intraocular fluid barriers. Exp Eye Res. 1972;14:233–241
  6. Bito LZ, Stjernschantz J, Resul B, et al.  The ocular effects of prostaglandins and the therapeutic potential of a new PGF2α analog, PhXA41 (latanoprost), for glaucoma management. J Lipid Mediators. 1993;6:535–543
  7. Cheng-Bennett A, Poyer J, Weinkam RJ, Woodward DF. Lack of prostaglandin F2α metabolism by human ocular tissues. Inv Ophthalmol Vis Sci. 1990;31:1389–1394
  8. Eakins KE, Atwal M, Bhattacherjee P. Inactivation of prostaglandin E1 by ocular tissues in vitro. Exp Eye Res. 1974;19:141–146
  9. Goh Y, Urade Y, Fujimoto N, Hayashi O. Content and formation of prostaglandins and distribution of prostaglandin-related enzyme activities in the rat ocular system. Biochim Biophys Acta. 1987;921:302–309
  10. Resul B, Stjernschantz J, No K, Liljebris C, et al.  Phenyl-substituted prostaglandins (potent and selective antiglaucoma agents). J Med Chem. 1993;36:243–248
  11. Schuster VL, Lu R, Coca-Prados M. The prostaglandin transporter is widely expressed in ocular tissues. Surv Ophthalmol. 1997;41(Suppl 2):S41–S45
  12. Sjöquist B, Basu S, Byding P, et al.  The pharmacokinetics of a new antiglaucoma drug, latanoprost, in the rabbit. Drug Metab Disp. 1998;26:745–754
  13. Sjöquist B, Tajallaei S, Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 1st communication (Single intravenous, oral or topical administration on the eye). Arzneimittelforschung. 1999;49:225–233
  14. Sjöquist B, Uhlin A, Byding P, Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 2nd communication (Repeated topical administration on the eye). Arzneimittelforschung. 1999;49:234–239
  15. Sjöquist B, Johansson A, Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 3rd communication (Tissue distribution after topical administration on the eye studied by whole body autoradiography). Arzneimittelforschung. 1999;49:240–249
  16. Stjernschantz J, Resul B. Phenyl substituted prostaglandin analogues for glaucoma treatment. Drugs Future. 1992;17:691–704
  17. Stjernschantz J, Alm A. Latanoprost as a new horizon in the medical management of glaucoma. Curr Opin Ophthalmol. 1996;7:11–17

PII: S0039-6257(02)00302-8

Survey of Ophthalmology
Volume 47 , Pages S6-S12 , August 2002

Article Tools

* Image Usage & Resolution